Thelansis

 Acromegaly is characterized by the progressive distortion of the body's features, primarily affecting the face and extremities but also impacting various organs throughout the body, resulting in systemic symptoms. It is closely linked to excessive growth hormone (GH) production. In over 90% of cases, this overproduction is triggered by a benign pituitary tumor called an adenoma. Due to its subtle onset and gradual progression, acromegaly is frequently not diagnosed until four to more than ten years after it begins, typically occurring in middle age, with the average age of onset ranging from 40 to 50 years. The prominent clinical signs include enlarged hands and feet, thickened and shortened fingers and increased soft tissue. The facial features include a broadened and consolidated nose, pronounced cheekbones, bulging forehead, thickened lips, and prominent facial lines. The forehead and overlying skin can become thicker, leading to a protruding appearance. There is a tendency for...

  Acromegaly is a disorder that occurs when your body makes too much growth hormone (GH). Produced mainly in the pituitary gland, GH controls the physical growth of the body. Acromegaly may also cause thickening of the body's soft tissues, including the heart, lips, and tongue. When the disease affects children prior to the end of puberty, excess growth hormone can lead to accelerated growth and tall stature, known as gigantism. Acromegaly affects between 3 and 14 people out of every 100,000. Thelansis’s “Acromegaly Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acromegaly treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and Chin...